146 related articles for article (PubMed ID: 31049278)
1. Aberrant Expression of Folate Metabolism Enzymes and Its Diagnosis and Survival Prediction in Ovarian Carcinoma.
Chen J; Li L
Anal Cell Pathol (Amst); 2019; 2019():1438628. PubMed ID: 31049278
[TBL] [Abstract][Full Text] [Related]
2. FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.
Huang MJ; Zhang W; Wang Q; Yang ZJ; Liao SB; Li L
J Ovarian Res; 2018 Feb; 11(1):15. PubMed ID: 29433550
[TBL] [Abstract][Full Text] [Related]
3. Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.
Kurosaki A; Hasegawa K; Kato T; Abe K; Hanaoka T; Miyara A; O'Shannessy DJ; Somers EB; Yasuda M; Sekino T; Fujiwara K
Int J Cancer; 2016 Apr; 138(8):1994-2002. PubMed ID: 26595060
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.
Köbel M; Madore J; Ramus SJ; Clarke BA; Pharoah PD; Deen S; Bowtell DD; Odunsi K; Menon U; Morrison C; Lele S; Bshara W; Sucheston L; Beckmann MW; Hein A; Thiel FC; Hartmann A; Wachter DL; Anglesio MS; Høgdall E; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Fogarty ZC; Vierkant RA; Liu S; Cho S; Nelson G; Ghatage P; Gentry-Maharaj A; Gayther SA; Benjamin E; Widschwendter M; Intermaggio MP; Rosen B; Bernardini MQ; Mackay H; Oza A; Shaw P; Jimenez-Linan M; Driver KE; Alsop J; Mack M; Koziak JM; Steed H; Ewanowich C; DeFazio A; Chenevix-Trench G; Fereday S; Gao B; Johnatty SE; George J; Galletta L; ; Goode EL; Kjær SK; Huntsman DG; Fasching PA; Moysich KB; Brenton JD; Kelemen LE
Br J Cancer; 2014 Dec; 111(12):2297-307. PubMed ID: 25349970
[TBL] [Abstract][Full Text] [Related]
5. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
[TBL] [Abstract][Full Text] [Related]
6. Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer.
Ginter PS; McIntire PJ; Cui X; Irshaid L; Liu Y; Chen Z; Shin SJ
Clin Breast Cancer; 2017 Nov; 17(7):544-549. PubMed ID: 28410844
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.
Notaro S; Reimer D; Fiegl H; Schmid G; Wiedemair A; Rössler J; Marth C; Zeimet AG
BMC Cancer; 2016 Aug; 16():589. PubMed ID: 27485273
[TBL] [Abstract][Full Text] [Related]
8. Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer.
Zhang M; Liu T; Xia B; Yang C; Hou S; Xie W; Lou G
Int J Gynecol Cancer; 2018 Feb; 28(2):323-331. PubMed ID: 29240605
[TBL] [Abstract][Full Text] [Related]
9. [Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer].
Li Z; Wang Q; Zhang W; Yang Z; Li L
Zhonghua Fu Chan Ke Za Zhi; 2015 Nov; 50(11):854-60. PubMed ID: 26887775
[TBL] [Abstract][Full Text] [Related]
10. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
Chen J; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
[TBL] [Abstract][Full Text] [Related]
12. Association of MTHFR, MTR, MTRR, RFC1, and DHFR gene polymorphisms with susceptibility to sporadic colon cancer.
Jokić M; Brčić-Kostić K; Stefulj J; Catela Ivković T; Božo L; Gamulin M; Kapitanović S
DNA Cell Biol; 2011 Oct; 30(10):771-6. PubMed ID: 21438757
[TBL] [Abstract][Full Text] [Related]
13. Association of Three Single Nucleotide Polymorphisms in MTR and MTRR Genes with Lung Cancer in a Turkish Population.
Aksoy-Sagirli P; Erdenay A; Kaytan-Saglam E; Kizir A
Genet Test Mol Biomarkers; 2017 Jul; 21(7):428-432. PubMed ID: 28537809
[TBL] [Abstract][Full Text] [Related]
14. MTRR silencing inhibits growth and cisplatin resistance of ovarian carcinoma via inducing apoptosis and reducing autophagy.
Chen J; Wang Q; Yin FQ; Zhang W; Yan LH; Li L
Am J Transl Res; 2015; 7(9):1510-27. PubMed ID: 26550452
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells.
Marverti G; Ligabue A; Lombardi P; Ferrari S; Monti MG; Frassineti C; Costi MP
Int J Oncol; 2013 Oct; 43(4):1269-80. PubMed ID: 23903781
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
[TBL] [Abstract][Full Text] [Related]
17. Dihydrofolate reductase as a predictor for poor response to platinum-based chemotherapy in epithelial ovarian cancer.
Wang M; Hu T; Xie KY
Int J Clin Exp Pathol; 2019; 12(5):1723-1730. PubMed ID: 31933990
[TBL] [Abstract][Full Text] [Related]
18. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.
Yuan Y; Nymoen DA; Dong HP; Bjørang O; Shih IeM; Low PS; Trope' CG; Davidson B
Hum Pathol; 2009 Oct; 40(10):1453-60. PubMed ID: 19454358
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and meta-analysis of higher expression of folate receptor alpha (FOLR1) predicts poor cancer prognosis.
Liu Y; Lian T; Yao Y
Biomarkers; 2020 Jul; 25(5):367-374. PubMed ID: 32421366
[TBL] [Abstract][Full Text] [Related]
20. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.
Kuhlmann JD; Wimberger P; Bankfalvi A; Keller T; Schöler S; Aktas B; Buderath P; Hauch S; Otterbach F; Kimmig R; Kasimir-Bauer S
Clin Chem; 2014 Oct; 60(10):1282-9. PubMed ID: 25015375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
